Statin Use and Mortality among Patients Hospitalized with Sepsis: A Retrospective Cohort Study within Southern California, 2008–2018

Table 3

Mortality risk comparison of statin use vs. nonuse of statins by biochemical property and of statins head-to-head.

HR (95% CI)	30-day mortality	90-day mortality
Statin use vs. nonuse	0.80 (0.77–0.83)	0.79 (0.77–0.81)
Statin properties
Synthetic vs. fungal	0.86 (0.81–0.91)	0.85 (0.81–0.89)
Hydrophilic vs. lipophilic	0.90 (0.81–1.01)	0.86 (0.78–0.94)
Specific drugs
Simvastatin (reference)
Atorvastatin	0.87 (0.82–0.92)	0.85 (0.81–0.90)
Lovastatin	1.22 (1.10–1.36)	1.19 (1.08–1.31)
Pravastatin	0.87 (0.76–0.98)	0.83 (0.74–0.92)
Rosuvastatin	0.85 (0.66–1.10)	0.77 (0.62–0.97)

Multivariable regressions modeling used adjusting for age, gender, race, liver disease, chronic kidney disease, heart failure, ischemic heart disease, chronic pulmonary disease, rheumatological disease, hypertension, cerebrovascular disease, diabetes mellitus I and II, dementia, malnutrition, peptic ulcer disease, all malignancy, organ transplantation, history of gastrointestinal hemorrhage, alcohol/drug use, HIV/AIDS, hyperlipidemia, biologic use, corticosteroid use, and disease modifying antirheumatologic drug use.